Hepatitis c virus markers in infection by hepatitis c virus:In the era of directly acting antivirals

World Journal of Gastroenterology

Volumn 21, Issue 38, 2015, Pages 10749-10759

  Coppola, Nicola ^a   Pisaturo, Mariantonietta ^a,b   Zampino, Rosa ^a   Macera, Margherita ^a   Sagnelli, Caterina ^a   Sagnelli, Evangelista ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Infectious Diseases   (Italy)

Author keywords

Chronic hepatitis C; Directly acting antivirals; Hepatitis C virus infection; Hepatitis C virus replication; Staging

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; EPITOPE; INTERLEUKIN 28; VIRUS RNA;

ABDOMINAL PAIN; ACUTE HEPATITIS C; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL PRACTICE; DISEASE SEVERITY; DNA SEQUENCE; ELASTOGRAPHY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; JAUNDICE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MALAISE; META ANALYSIS (TOPIC); NAUSEA; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; BLOOD; COMBINATION DRUG THERAPY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; BIOMARKERS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; RNA, VIRAL; VIRAL LOAD;

EID: 84944049133     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i38.10749     Document Type: Article

References (132)

1. Sagnelli E, Santantonio T, Coppola N, Fasano M, Pisaturo M, Sagnelli C. Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. Infection 2014; 42: 601-610 [PMID: 24619833 DOI: 10.1007/s15010-014-0608-2]
2. Sagnelli E, Tonziello G, Pisaturo M, Sagnelli C, Coppola N. Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. Antivir Ther 2012; 17: 1453-1458 [PMID: 23322703 DOI: 10.3851/IMP2471]
3. Sagnelli E, Coppola N, Marrocco C, Coviello G, Rossi G, Battaglia M, Sagnelli C, Messina V, Tonziello A, Scolastico C, Filippini P. Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation. J Biol Regul Homeost Agents 2003; 17: 207-210 [PMID: 14518726]
4. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, Rossi G, Sagnelli C, Scolastico C, Filippini P. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005; 42: 646-651 [PMID: 15826712]
5. Coppola N, Pisapia R, Marrocco C, Martini S, Vatiero LM, Messina V, Tonziello G, Sagnelli C, Filippini P, Piccinino F, Sagnelli E. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007; 40: 110-115 [PMID: 17720621]
6. Coppola N, Vatiero LM, Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut 2005; 54: 1207 [PMID: 16009701]
7. Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 1174-1180.e11 [PMID: 23591280]
8. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46 [PMID: 12407575]
9. Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013; 35: 111-120 [PMID: 23010890 DOI: 10.1007/s00281-012-0330-z]
10. Dohmen K, Kawano A, Takahashi K, Shigematsu H, Tanaka H, Haruno M, Yanagita K, Ichiki Y, Mori T, Hayashida K, Shimoda S, Ishibashi H, Nomura H. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Hepatogastroenterology 2013; 60: 2034-2038 [PMID: 24719946]
11. Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. J Viral Hepat 2014; 21: 357-365 [PMID: 24716638 DOI: 10.1111/jvh.12151]
12. Ishikawa T. Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. World J Gastroenterol 2013; 19: 6127-6130 [PMID: 24115808 DOI: 10.3748/wjg.v19. i37.6127]
13. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacifc region. J Gastroenterol 2013; 48: 681-688 [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9]
14. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010; 25: 657-663 [PMID: 20492323 DOI: 10.1111/j.1440-1746.2009.06167.x]
15. Kanda T, Yokosuka O, Omata M. Hepatitis C virus and hepatocellular carcinoma. Biology (Basel) 2013; 2: 304-316 [PMID: 24832662 DOI: 10.3390/biology2010304]
16. Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, Miyahara K, Onishi H, Nakamura S, Yamamoto K, Shimizu K. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol 2012; 27: 797-804 [PMID: 22004425 DOI: 10.1111/j.1440-1746.2011.06948.x]
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep. 2011.02.023]
18. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis 2012; 12: 357 [PMID: 23245594 DOI: 10.1186/1471-23 34-12-357]
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]
20. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012; 107: 669-689; quiz 690 [PMID: 22525303 DOI: 10.1038/ajg.2012.48]
21. European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 Suppl 1: 2-8 [PMID: 22212565 DOI: 10.1111/j.1478-3231.2011.02703.x]
22. Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother 2014; 15: 1337-1349 [PMID: 24773464 DOI: 10.1517/14656566.2014.913571]
23. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One 2014; 9: e94542 [PMID: 24728219 DOI: 10.1371/journal.pone.0094542]
24. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa10 10494]
25. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
26. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
27. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
28. Dieterich DT, Soriano V, Sherman K, Girard PM, Rockstroh J, Adiwijaya B, McCallister S, Adda N, Mahnke L, Sulkowski MS; on behalf of the Study 110 Team. Telaprevir in combination with pegylated interferon-a-2a RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. March 5-8-2012, [abstract #46]. In: Conference on Retroviruses and Other Opportunistic Infections. Seattle: WA, 2012
29. Sulkowski MS, Pol S, Cooper C, Fainboim H, Slim J, Rivero A Laguno M, Thompson S, Wahl J, Greaves W. Boceprevir pegylated interferon ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (week 48) interim results. March 5-8 2012, [Abstract #47]. In: Conference on Retroviruses and Other Opportunistic Infections. Seattle: WA, 2012
30. Montes M, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J. Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks fnal analysis. J Int AIDS Soc 2014; 17: 19626 [PMID: 25394130 DOI: 10.7448/IAS.17.4.19626]
31. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84 [PMID: 21827730 DOI: 10.1016/j.jhep.2011.07.016]
32. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH. Effcacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fbrosis/cirrhosis. J Hepatol 2013; 58: 479-487 [PMID: 23183529 DOI: 10.1016/j.jhep.2012.11.020]
33. Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol 2015; 4: 1-12 [PMID: 25674512 DOI: 10.5501/wjv.v4.i1.1]
34. Cotte L, Barrail-Tran A, Vincent C, Valantin MA, Fournier I, Lacombe K, Chevaliez S, Aboulker JP, Taburet AM, Molina JM; ANRS HC26 study group. Telaprevir enhances ribavirin-induced anaemia through renal function impairment. Antivir Ther 2015; Epub ahead of print [PMID: 25560644 DOI: 10.3851/IMP2929]
35. Koff RS. Review article: the effcacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-487 [PMID: 24387618 DOI: 10.1111/apt.12601]
36. Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013; 20: 3733-3742 [PMID: 23848533]
37. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
38. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
39. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]
40. Documento di indirizzo dell'Associazione Italiana per lo studio del Fegato per l'uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilità in Italia. AISF 24/02/2015. Available from: URL: http://www.webaisf.org
41. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33: 321-327 [PMID: 11172332]
42. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology 2008; 47: 321-331 [PMID: 18161707]
43. Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T. The natural history of acute hepatitis C: clinical presentation, laboratory fndings and treatment outcomes. Aliment Pharmacol Ther 2011; 33: 559-565 [PMID: 21198704 DOI: 10.1111/j.1365-2036.2010.04549]
44. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-S73 [PMID: 12407578]
45. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500 [PMID: 2509915]
46. Lu SN, Tung HD, Chen TM, Lee CM, Wang JH, Hung CH, Chen CH, Changchien CS. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion? J Viral Hepat 2004; 11: 563-570 [PMID: 15500558]
47. Araujo AC, Astrakhantseva I V, Fields HA, Kamili S. Distinguishing acute from chronic hepatitis C virus (HCV) infection based on antibody reactivities to specifc HCV structural and nonstructural proteins. J Clin Microbiol 2011; 49: 54-57 [PMID: 21084519 DOI: 10.1128/JCM.01064-10]
48. Sheen IS, Liaw YF, Lin DY, Chu CM. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. J Hepatol 1996; 24: 525-531 [PMID: 8773906]
49. Hiraga N, Suzuki F, Akuta N, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Matsuda M, Watabiki S, Satoh J, Kumada H. Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase fare-up. J Med Virol 2005; 75: 240-248 [PMID: 15602722]
50. Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402-406 [PMID: 15710990]
51. Ward KN, Dhaliwal W, Ashworth KL, Clutterbuck EJ, Teo CG. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J Med Virol 1994; 43: 367-372 [PMID: 7525865]
52. Kanno A, Kazuyama Y. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection. J Med Virol 2002; 68: 229-233 [PMID: 12210412]
53. Coppola N, Pisapia R, Tonziello G, Masiello A, Martini S, Pisaturo M, Messina V, Sagnelli C, Macera M, Signoriello G, Sagnelli E. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009; 46: 222-229 [PMID: 19758839 DOI: 10.1016/j.jcv.2009.08.009]
54. Gaudy-Graffn C, Lesage G, Kousignian I, Laperche S, Girault A, Dubois F, Goudeau A, Barin F. Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection. J Clin Microbiol 2010; 48: 3281-3287 [PMID: 20610669 DOI: 10.1128/JCM.00303-10]
55. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714 [PMID: 16702586]
56. Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ 2007; 56: 1-24 [PMID: 17363893]
57. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004; 141: 715-717 [PMID: 15520428]
58. Hosein SR, Wilson DP. HIV, HCV, and drug use in men who have sex with men. Lancet 2013; 382: 1095-1096 [PMID: 24075047 DOI: 10.1016/S0140-6736(13)62020-6]
59. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24: 1799-1812 [PMID: 20601854 DOI: 10.1097/QAD.0b013e32833c11a5]
60. Urbanus AT, Van De Laar TJ, Geskus R, Vanhommerig JW, Van Rooijen MS, Schinkel J, Heijman T, Coutinho RA, Prins M. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. AIDS 2014; 28: 781-790 [PMID: 24832014 DOI: 10.1097/QAD.0000000000000126]
61. Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill 2011; 16: pii: 20031 [PMID: 22172300]
62. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specifcity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001; 8: 87-95 [PMID: 11264728]
63. Dufour DR, Talastas M, Fernandez MD, Harris B. Chemi-luminescence assay improves specificity of hepatitis C antibody detection. Clin Chem 2003; 49: 940-944 [PMID: 12765991]
64. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 1-13, 15; quiz CE1-CE4 [PMID: 12585742]
65. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, Dhumeaux D. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-1702 [PMID: 9620345]
66. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68: 15-18 [PMID: 7536987]
67. Morishima C, Gretch DR. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. Clin Liver Dis 1999; 3: 717-740 [PMID: 11291247]
68. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 558-566 [PMID: 23070489 DOI: 10.7326/0003-4819-157-8-20121 0160-00006]
69. Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013; 62: 362-365 [PMID: 23657112]
70. Saldanha J. Sensitivity of PCR assays for the determination of hepatitis A virus RNA in plasma pools. A collaborative study. Vox Sang 1999; 76: 163-165 [PMID: 10341331]
71. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-1340 [PMID: 8675148]
72. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW. Recommendations for the identifcation of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32 [PMID: 22895429]
73. Sagnelli E, Sagnelli C, Pisaturo MA, Coppola N, Pasquale G, Piccinino F. Liver biopsy in chronic hepatitis C: the experience of 15 Italian wards of infectious diseases. Infez Med 2012; 20: 31-36 [PMID: 22475658]
74. Pasquale G, Sagnelli E, Coppola N, Onofrio M, Scarano F, Scolastico C, Bellomo PF, Lettieri A, Mogavero AR, Caprio N, Sagnelli C, Piccinino F. [An attempt to improve classifcation of HCV-correlated chronic hepatitis]. Infez Med 2005; 13: 16-22 [PMID: 15888977]
75. Sagnelli E, Pasquale G, Coppola N, Marrocco C, Scarano F, Imparato M, Sagnelli C, Scolastico C, Piccinino F. Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis. J Med Virol 2005; 75: 222-226 [PMID: 15602732]
76. Sagnelli E, Pasquale G, Coppola N, Scarano F, Marrocco C, Scolastico C, Santantonio T, Gentile A, Piccinino F. Infuence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004; 32: 144-148 [PMID: 15188073]
77. Sagnelli E, Coppola N, Scolastico C, Filippini P, Piccinino F. [Virological and clinical aspects of multiple hepatitis virus infections: preliminary data of an italian multicentre study] Infez Med 1999; 7: 90-95 [PMID: 12759587]
78. Pasquale G, Sagnelli E, Coppola N, Scarano F, Scolastico C, Sagnelli C, Bellomo PF, Lettieri A, Filippini P, Piccinino F. Uselessness of liver biopsy in patients with hepatitis C virus chronic infection and persistently normal aminotransferase levels. Infez Med 2003; 11: 11-17 [PMID: 12719665]
79. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64: 350-355 [PMID: 11424125]
80. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713 [PMID: 14698338]
81. Chon YE, Choi EH, Song KJ, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH, Kim SU. Performance of transient elastography for the staging of liver fbrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One 2012; 7: e44930 [PMID: 23049764 DOI: 10.1371/journal.pone.0044930]
82. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659 [PMID: 21146892 DOI: 10.1016/j.jhep.2010.07.033]
83. Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172: 389-392 [PMID: 2526349 DOI: 10.1148/radiology]
84. Aubé C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy J Y, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Riffet H, Maïga MY, Penneau-Fontbonne D, Caron C, Calès P. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472-478 [PMID: 10190731]
85. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-S56 [PMID: 12407576]
86. Marcellin P, Akrémi R, Cazals D, Boyer N, Aupérin A, Vidaud D, Degott C. Genotype 1 is associated with a slower progression of fbrosis in un-treated patients with mild chronic hepatitis C. J Hepatol 2001; 34 (Suppl 1): 159
87. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of fbrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104 [PMID: 12512034]
88. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, Degott C, Valla DC, Marcellin P. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-1005 [PMID: 11679971]
89. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fbrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-872 [PMID: 9500720]
90. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, Sasso FC, Torella R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-764 [PMID: 10734027]
91. Pasquale G, Sagnelli E, Coppola N, Scarano F, Scolastico C, Bellomo PF, Lettieri A, Piccinino F. Is liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels? Eur J Gastroenterol Hepatol 2003; 15: 831-833 [PMID: 12811317]
92. Chou R, Wasson N. Blood tests to diagnose fbrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med 2013; 159: 372 [PMID: 24026329 DOI: 10.7326/0003-4819-159-5-201309030-00021]
93. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan S Y. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fbrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736 [PMID: 21319189 DOI: 10.1002/hep.24105]
94. Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400 [PMID: 23278163 DOI: 10.1111/apt.12186]
95. Wai CT, Greenson JK, Fontana RJ, Kalbfeisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]
96. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075 [PMID: 11297957 DOI: 10.1016/S0140-6736(00)04258-6]
97. Kim BK, Kim SU, Kim HS, Park JY, Ahn SH, Chon CY, Cho IR, Joh DH, Park YN, Han KH, Kim do Y. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fbrosis in Asian subjects with chronic hepatitis B. PLoS One 2012; 7: e35825 [PMID: 22536445 DOI: 10.1371/journal.pone.0035825]
98. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40 [PMID: 17937811 DOI: 10.1186/1471-230X-7-40]
99. Poynard T, Munteanu M, Ngo Y, Castera L, Halfon P, Ratziu V, Imbert-Bismut F, Thabut D, Bourliere M, Cacoub P, Messous D, de Ledinghen V. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol 2010; 34: 388-396 [PMID: 20580175 DOI: 10.1016/j.gcb.2010.05.001]
100. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fbrosis scoring systems can reliably exclude advanced fbrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269 [PMID: 20801772 DOI: 10.1136/gut.2010.216077]
101. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. Development of a simple noninvasive index to predict signifcant fbrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325 [PMID: 16729309 DOI: 10.1002/hep.21178]
102. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36 [PMID: 17567829 DOI: 10.1002/hep.21669]
103. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrère JJ, Pawlotsky JM, De Micco P, Laperche S. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-1145 [PMID: 17251399]
104. Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolf LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014; 33: 559-567 [PMID: 24081499 DOI: 10.1007/s10096-013-1985-7]
105. Coppola N, Rosa Z, Cirillo G, Stanzione M, Macera M, Boemio A, Grandone A, Pisaturo M, Marrone A, Adinolf LE, Sagnelli E, Miraglia Del Giudice E. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int 2015; 35: 1959-1963 [PMID: 25581573 DOI: 10.1111/liv.12781]
106. Zampino R, Coppola N, Cirillo G, Boemio A, Minichini C, Marrone A, Stanzione M, Starace M, Durante-Mangoni E, Sagnelli E, Restivo L, Salzillo G, Fascione MC, Nevola R, Del Giudice EM, Adinolf LE. Insulin resistance and steatosis in HBV-HCV coinfected patients: Role of PNPLA3 polymorphisms and impact on liver fbrosis progression. World J Hepatol 2014; 6: 677-684 [PMID: 25276284 DOI: 10.4254/wjh.v6.i9.677]
107. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]
108. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna K V, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.e18 [PMID: 20399780 DOI: 10.1053/j.gastro.2010.04.013]
109. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244 [PMID: 12407599]
110. Zampino R, Alessio L, Marrone A, Stanzione M, Boemio A, Grandone A, Minichini C, Pisaturo M, Starace M, Adinolfi LE, Sagnelli E, Coppola N. Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. Infez Med 2015; 23: 134-139 [PMID: 26110293]
111. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408 [PMID: 20173735 DOI: 10.1038/nature08825]
112. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011; 53: 389-395 [PMID: 21274861 DOI: 10.1002/hep.24068]
113. Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir Ther 2011; 16: 685-694 [PMID: 21817190 DOI: 10.3851/IMP1796]
114. Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, Thompson AJ, Shianna KV, Vispo E, McHutchison JG, Goldstein DB, Soriano V. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis 2012; 205: 376-383 [PMID: 22158703 DOI: 10.1093/infdis/jir754]
115. Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4: 54-60 [PMID: 23919217 DOI: 10.4292/wjgpt.v4.i3.54]
116. Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010; 42: 81-91 [PMID: 19748329 DOI: 10.1016/j.dld.2009.08.001]
117. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI: 10.1002/hep.24641]
118. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. Geneva: World Health Organization, 2014 [PMID: 25535634]
119. Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004; 40: 1442-1449 [PMID: 15565603]
120. Carlsson T, Reichard O, Norkrans G, Bläckberg J, Sangfelt P, Wallmark E, Weiland O. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005; 12: 473-480 [PMID: 16108761]
121. Durante-Mangoni E, Zampino R, Portella G, Adinolf LE, Utili R, Ruggiero G. Correlates and prognostic value of the frst-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis 2009; 49: 498-506 [PMID: 19591593 DOI: 10.1086/600887]
122. Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-921 [PMID: 19852962 DOI: 10.1053/j.gastro.2009.10.033]
123. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. Chemical genetics strategy identifes an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100 [PMID: 20410884 DOI: 10.1038/nature08960]
124. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 2013; 110: 3991-3996 [PMID: 23431163 DOI: 10.1073/pnas.1203110110]
125. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58: 663-668 [PMID: 23183528 DOI: 10.1016/j.jhep.2012.11.018]
126. Sarrazin C, Wedemeyer H, Cloherty G, Cohen DE, Chevaliez S, Herman C, Bernstein B, Pawlotsky JM. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods 2015; 214: 29-32 [PMID: 25528998 DOI: 10.1016/j.jviromet.2014.11.027]
127. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]
128. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]
129. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]
130. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-365.e1 [PMID: 24818763 DOI: 10.1053/j.gastro.2014.04.045]
131. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H. Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. Hepatol Res 2007; 37: 787-792 [PMID: 17573943]
132. Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-429 [PMID: 24184132 DOI: 10.1053/j.gastro.2013.10.057]